Does Intramuscular Estrogen Affect Kidney Function or GFR?
Estrogen does not directly damage kidney function in healthy individuals, but it significantly alters the pharmacokinetics and assessment of renal function, particularly in patients with pre-existing chronic kidney disease (CKD), where reduced renal clearance leads to 2-3 times higher serum estradiol concentrations requiring 50-70% dose reduction. 1
Impact on Kidney Function Assessment
Changes in Creatinine and GFR Estimation
Estrogen therapy causes a decrease in lean body mass (approximately 2.4 kg reduction), which directly reduces creatinine generation and can falsely suggest improved kidney function when using creatinine-based eGFR calculations. 2
After at least 1 year of estrogen therapy, creatinine reference ranges and eGFR calculations should be interpreted based on the affirmed gender rather than sex assigned at birth, as creatinine levels shift toward female reference ranges. 2
For the most accurate kidney function assessment in patients on estrogen therapy, cystatin C-based eGFR is preferred because it is less dependent on muscle mass and dietary intake, though it is not widely available. 2
Conflicting Evidence on Actual GFR Effects
The evidence regarding estrogen's true effect on kidney function shows contradictory findings:
Potential beneficial effects:
- Multiple observational studies demonstrate that estrogen therapy is associated with higher measured GFR in postmenopausal women. 3, 4, 5
- A 2025 Mendelian randomization study found a positive causal relationship between serum estradiol concentration and eGFR, particularly significant in populations with CKD and hypertension. 6
- Cross-sectional data from 1,044 postmenopausal women showed current estrogen users had lower odds of chronic kidney disease and better preserved diastolic blood pressure. 5
Potential harmful effects:
- A 2008 study of 5,845 elderly women (over age 66) found that oral estrogen use was associated with significant loss of eGFR in a dose-dependent manner, though transdermal estrogen was not associated with this decline. 7
- This suggests route of administration may be critical, with oral estrogen potentially having different renal effects than parenteral routes.
Critical Dosing Considerations in CKD
Altered Pharmacokinetics
Patients with CKD have dramatically reduced renal clearance of estrogen, with urinary excretion dropping from 78-83% in normal renal function to only 1.4% in CKD patients. 1
After a single dose of estradiol, serum concentrations of estradiol and estrone are 2-3 times higher in CKD patients compared to controls. 1
Even with a 50% dose reduction, postmenopausal women with CKD on hemodialysis had estradiol serum concentrations over 20% greater than women with normal renal function. 1
Dosing Algorithm for CKD Patients
For patients with CKD requiring estrogen therapy:
Reduce the standard estrogen dose by 50-70% to achieve equivalent serum concentrations as patients with normal renal function. 1
Monitor serum estradiol levels (and possibly FSH levels) to guide dosing, as benefit is related to blood concentration rather than actual dose. 1
Excessively high blood concentrations may cause dose-dependent harms including increased risk of breast cancer, coagulopathy, and coronary artery disease. 1
Monitoring Recommendations
For Patients on Estrogen Therapy
Monitor renal function at 3-month intervals in patients with CKD stage 3-4, as anecdotal reports exist of increases in serum creatinine. 8
If an unexplained decrease in eGFR occurs, consider stopping estrogen therapy. 8
Record the duration of hormone therapy, dose, and route of administration when interpreting laboratory values. 2
For patients who have stopped estrogen therapy, laboratory values typically reflect sex assigned at birth within 3 months of discontinuation. 2
Additional Precautions
Estrogen should be used with caution in patients with conditions that may be influenced by fluid retention, including cardiac or renal dysfunction, as estrogens may cause some degree of fluid retention. 9
Common Pitfalls to Avoid
Do not use standard creatinine-based eGFR equations without considering the duration and type of hormone therapy, as this may lead to mischaracterization of kidney function. 2
Do not assume that improved eGFR on estrogen therapy represents true improvement in kidney function, as this may reflect decreased creatinine generation from reduced muscle mass rather than improved filtration. 2
Do not use standard estrogen doses in patients with CKD, as this leads to excessive serum concentrations and potential harm. 1
Be aware that the route of administration matters: oral estrogen may have different renal effects than intramuscular or transdermal routes. 7